Clinical Context
A patient presents to the emergency department or inpatient unit with suspected or confirmed severe falciparum malaria, or another severe parasitic infection for which parenteral artesunate is indicated. Typical presentation includes high-grade fever, rigors, altered mental status, hypotension, hemolysis, respiratory distress, or multi-organ dysfunction. Rapid diagnosis is supported by positive malaria smear or rapid diagnostic test. Intravenous artesunate (J0391, injection, artesunate, 1 mg) is administered as weight‑based dosing (commonly 2.4 mg/kg per dose for adults and children) at 0, 12, and 24 hours and then daily until oral therapy can be tolerated. The clinical workflow includes triage and stabilization, laboratory confirmation (CBC, metabolic panel, blood smear), weight measurement, preparation of artesunate by pharmacy, administration by nursing with monitoring for therapeutic response and adverse events (e.g., delayed hemolysis), documentation of dose, lot number, and any wasted product, and transition to oral antimalarial therapy (such as artemisinin-based combination therapy) once clinically appropriate. Typical site of service is the hospital inpatient unit or emergency department; use may also occur in outpatient infusion centers for urgent parenteral antimalarial therapy when clinically necessary. Common payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.